Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H15ClN2.ClH |
| Molecular Weight | 307.218 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCN=C(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3
InChI
InChIKey=XBWAZCLHZCFCGK-UHFFFAOYSA-N
InChI=1S/C16H15ClN2.ClH/c1-19-10-9-18-16(12-5-3-2-4-6-12)14-11-13(17)7-8-15(14)19;/h2-8,11H,9-10H2,1H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H15ClN2 |
| Molecular Weight | 270.757 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Medazepam is a benzodiazepine drug with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is known by the following brand names: Azepamid, Nobrium, Tranquirax (mixed with bevonium), Rudotel, Raporan, Ansilan and Mezapam. Marketed in Russia. Indicated for the treatment of neurotic disorders and states, accompanied with sense of fear, anxiety, intension, raised irritability, insomnia, vegetative lability.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 170.0 µM [IC50] | |||
Target ID: CHEMBL1907607 |
528.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Nobrium Approved UseThis medication is used in the treatment of anxiety disorders, alcohol withdrawal, tremor, muscle spasms and to control seizures. It may also be used before surgery or procedures to reduce apprehension and anxiety. |
|||
| Primary | Nobrium Approved UseThis medication is used in the treatment of anxiety disorders, alcohol withdrawal, tremor, muscle spasms and to control seizures. It may also be used before surgery or procedures to reduce apprehension and anxiety. |
|||
| Primary | Nobrium Approved UseThis medication is used in the treatment of anxiety disorders, alcohol withdrawal, tremor, muscle spasms and to control seizures. It may also be used before surgery or procedures to reduce apprehension and anxiety. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Medazepam compared with amylobarbitone in treatment of anxiety. | 1971 Jan 16 |
|
| Bromazepam, medazepam, chlordiazepoxide in treatment of neurotic anxiety. | 1974 May |
|
| Structural requirements of benzodiazepines for the inhibition of pig brain nitric oxide synthase. | 2001 Nov 30 |
|
| [Analysis of benzodiazepine derivative mixture by gas-liquid chromatography]. | 2002 |
|
| Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. | 2002 Apr |
|
| Quantitation using GC-TOF-MS: example of bromazepam. | 2002 Aug 14 |
|
| Oesophageal motility disorders. | 2002 Jan 12 |
|
| A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. | 2002 Mar 10 |
|
| Square-wave voltammetric techniques for determination of psychoactive 1,4-benzodiazepine drugs. | 2002 Nov |
|
| Direct injection micellar liquid chromatographic determination of benzodiazepines in serum. | 2002 Nov 25 |
|
| [Determination of diazepine derivatives: alprazolam, medazepam, chlordiazepoxid mixture by high performance liquid chromatography]. | 2003 |
|
| [Comprehensive medical and ecological studies in Pryel'brussi]. | 2003 |
|
| A study into the rate of incorporation of eight benzodiazepines into rat hair. | 2003 Apr 23 |
|
| Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. | 2003 Feb 1 |
|
| Pharmacological activity of phenazepam and flunitrazepam in ultralow doses. | 2003 Jan |
|
| Determination of clofazimine in leprosy patients by high-performance liquid chromatography. | 2003 Sep |
|
| Mountain sports and total hip arthroplasty: a case report and review of mountaineering with total hip arthroplasty. | 2003 Summer |
|
| Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2004 Aug |
|
| Determination of diazepam in cream biscuits by liquid chromatography. | 2004 May-Jun |
|
| Diagnostic imaging in Canada. | 2005 |
|
| Risk and benefit of drug use during pregnancy. | 2005 |
|
| Application of surface ionization methods for highly sensitive and selective analysis of benzodiazepine derivatives. | 2005 Apr 29 |
|
| [The nitric oxide system in patients with arterial hypertension living in high mountains]. | 2007 |
|
| Cytokinin-binding protein (70 kDa): localization in tissues and cells of etiolated maize seedlings and its putative function. | 2007 |
|
| Separation of 1,4-benzodiazepines by micellar elektrokinetic capillary chromatography. | 2007 Jan 10 |
|
| Human resource management in the Georgian National Immunization Program: a baseline assessment. | 2007 Jul 31 |
|
| [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. | 2008 |
|
| The educational background and qualifications of UK medical students from ethnic minorities. | 2008 Apr 16 |
|
| Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain. | 2008 Aug 19 |
|
| A study of the effects of large doses of medazepam used for self-poisoning in 10 pregnant women on fetal development. | 2008 Feb-Mar |
|
| OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism. | 2009 Aug |
|
| Benzodiazepine prescription and length of hospital stay at a Japanese university hospital. | 2009 Oct 9 |
|
| Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
| Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology. | 2010 Aug 1 |
|
| From their own perspective - constraints in the Polio Eradication Initiative: perceptions of health workers and managers in a district of Pakistan's Punjab province. | 2010 Aug 23 |
|
| Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples. | 2010 Jan |
|
| Framing access to medicines in developing countries: an analysis of media coverage of Canada's Access to Medicines Regime. | 2010 Jan 4 |
|
| Cytokinin-binding protein (70 kDa) from etioplasts and amyloplasts of etiolated maize seedlings and chloroplasts of green plants and its putative function. | 2010 Jul |
|
| Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. | 2010 Jun |
|
| Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines. | 2010 Mar 15 |
|
| Randomised controlled trial of integrated care to reduce disability from chronic low back pain in working and private life. | 2010 Mar 16 |
|
| [Oxygen consumption by resting humans at different Elbrus altitudes]. | 2010 May-Jun |
|
| A new method for the simultaneous determination of 1,4-benzodiazepines and amfepramone as adulterants in phytotherapeutic formulations by voltammetry. | 2010 Oct 10 |
|
| Effectiveness of additional supervised exercises compared with conventional treatment alone in patients with acute lateral ankle sprains: systematic review. | 2010 Oct 26 |
|
| Daily functioning and self-management in patients with chronic low back pain after an intensive cognitive behavioral programme for pain management. | 2010 Sep |
|
| 1-(1-Phenyl-ethyl-idene)carbonohydrazide. | 2010 Sep 30 |
Patents
Sample Use Guides
The average dose for adults: single - 10-20 mg, the average daily - 20-30 mg, the maximum - 60-70 mg / day. At the beginning of treatment - for 5 mg 2-3 times a day, then gradually increase the dose to 30-40 mg per day. In outpatient settings recommended by 5 mg in the morning and in the afternoon, and 10 mg in the evening. Elderly patients, teenagers, as well as kidney function - 5-10 mg 1-2 times a day, or 10 mg at night. Babies dose depends on the age and body weight. Treatment duration should be as short as possible (about 2 Sun) and should not exceed 2 Months (including the period of gradual reduction of the dose).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:09:47 GMT 2023
by
admin
on
Fri Dec 15 19:09:47 GMT 2023
|
| Record UNII |
ETM878JC9K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1012
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB35638
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL28333
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | |||
|
C66069
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | |||
|
ETM878JC9K
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | |||
|
100000128530
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | |||
|
169896
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | |||
|
17930
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | |||
|
DTXSID50951593
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | |||
|
2898-11-5
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | |||
|
220-782-9
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | |||
|
m7127
Created by
admin on Fri Dec 15 19:09:47 GMT 2023 , Edited by admin on Fri Dec 15 19:09:47 GMT 2023
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |